A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Brief description of study
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
lymphoma, cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
11 Mar 2020.
Study ID: 829921
